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Abstract
Purpose: Focal nodular hyperplasia (FNH) and hepatocellular adenoma (HCA) are liver tumors that
require different management. We assessed the potential of point shear wave elastography
(pSWE) to differentiate FNH from HCA and the interobserver and intraobserver reliability of
pSWE in the examination of these lesions and of native liver tissue (NLT).
Methods: The study included 88 patients (65 FNH, 23 HCA). pSWE was performed by two experi-
enced liver sonographers (observers 1 [O1] and 2 [O2]) and acquired within the lesion of interest
and NLT. Group differences, optimal cutoff for characterization and interobserver reliability was
assessed with Mann-Whitney-U, area under the ROC curce (AUROC) and intraclass correlation
coefficient (ICC). Intraobserver reliability in NLT was assessed in 20 healthy subjects using ICC.
Results: Median stiffness was significantly higher in FNH than in HCA (7.01 kPa vs 4.98 kPa for
O1 (P50.017) and 7.68 kPa vs 6.00 kPa for O2 (P50.031)). A cutoff point for differentiation
between the two entities could not be determined with an AUROC of 0.67 (O1) and 0.69 (O2).
Interobserver reliability was good for lesion- stiffness (ICC50.86) and poor for NLT stiffness
(ICC50.09). In healthy subjects, intraobserver reliability for NLT-stiffness was poor for O1
(ICC50.23) and moderate for O2 (ICC50.62).
Conclusion: This study shows that pSWE cannot reliably differentiate FNH from HCA. Interob-
server and intraobserver reliability for pSWE in NLT were insufficient. Interpretation of results
gained with this method should be done with great caution.
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1 | INTRODUCTION
Focal nodular hyperplasia (FNH) and hepatocellular adenoma (HCA) are
two clinically important benign focal liver lesions. Histologically, these
two lesions differ. FNH is in fact a pseudotumor with a large part
consisting of fibrotic stroma making the lesion stiff, while HCA does
not have a substantial fibrotic component and has a consistency similar
to that of healthy liver tissue.1
Differentiating between these two lesions is essential because
each requires specific management. Follow-up of FNH is not necessary,
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provided the correct diagnosis has been made, but HCA often needs to
be resected or at least monitored in view of the risk of bleeding or
transformation into hepatocellular carcinoma.2,3 The current standard
diagnostic workup includes either contrast-enhanced ultrasound
(CEUS) or contrast-enhanced MRI (CE-MRI).4–7 The estimated sensitiv-
ity and specificity of CEUS in the differentiation of FNH from HCA are
67% and 100%, respectively, with a significantly reduced sensitivity in
lesions >35 mm.8 For CE-MRI with hepatocellular specific contrast, the
sensitivity is estimated at 91%–100% and the specificity at 87%–
100%.9 When the diagnosis remains uncertain, these patients may
undergo a tumor biopsy.10 In order to avoid a percutaneous biopsy and
the associated risk of complications11 or even the surgical resection of
a suspect lesion that turns out to be FNH, improvement of the diagnos-
tic process is needed.
The first ultrasound elastography method for the liver became
available in 2003 in the form of transient elastography with the Fibro-
scan device.12 This method uses a mechanic pulse to measure the stiff-
ness of the liver tissue. In 2008, a new elastography technique named
Acoustic Radiation Force Impulse quantification (ARFI®, Siemens)
became available and was incorporated in the ultrasound scanner. This
method uses ultrasound point shear wave elastography (pSWE) and
measures the speed of the shear wave (perpendicular to the axis of the
ultrasound beam) in a small region at a selected depth within 80 mm
from the skin. Other companies have started to develop similar tech-
nologies, including ElastPQ® by Philips Healthcare. pSWE can be used
as a noninvasive, reproducible, and easy method of assessing liver
fibrosis. A few preliminary studies have shown that pSWE can also be
used to measure the stiffness of focal liver lesions such as FNH or
HCA and can help in differentiating between these lesions, especially if
the lesions are small.13–16
The primary aim of this study was to assess the diagnostic value of
pSWE (ElastPQ®, Phillips Healthcare) in the differentiation between
FNH and HCA. We also intended to assess the interobserver and intra-
observer reliability of pSWE in the evaluation of these liver lesions and
in the native liver tissue (NLT).
2 | PATIENTS AND METHODS
This diagnostic study was performed in a tertiary referral center for
focal liver lesions and was approved by the accredited local institutional
review board.
2.1 | Patients with FNH or HCA
Patients diagnosed with FNH or HCA between January 1st 2007 and
November 30th 2016 were eligible. All patients who first underwent
CEUS and subsequently had either contrast enhanced MRI (CE-MRI) or
biopsy confirming the diagnosis were included. When available, histo-
logical diagnosis was considered as the reference standard. In all other
cases, the final diagnosis was discussed during a multidisciplinary tumor
board (with radiologists, hepatologists and surgeons) and based on the
combination of CEUS and CE-MRI characteristics. Patients who under-
went previous intervention for treatment of FNH or HCA or had
severe other liver disease (eg, cirrhosis, hepatocellular carcinoma, liver
metastasis) were excluded. In addition, women over the age of 50 with
an HCA were excluded, as these lesions often regress after
menopause.17
We identified potentially eligible patients from the electronic data-
bases of the departments of Gastroenterology and Hepatology and Sur-
gery of the Erasmus MC, Rotterdam. Information on sex, date of birth,
date of diagnosis, lesion diameter at diagnosis, CEUS diagnosis, CE-MRI
diagnosis, and histological diagnosis was retrieved from electronic
patient records. CEUS and CE-MRI diagnoses were based on typical
imaging characteristics.4–7 HCA subtype (eg, steatotic, inflammatory,
beta-catenin mutated or unclassified) was based on CE-MRI7,18,19 or
biopsy.20 An experienced abdominal radiologist (M.T. with 20 years of
experience) reviewed the CE-MRI examinations of patients in whom
HCA subtype was not yet established and determined that subtype.
2.2 | Healthy subjects
We asked 20 healthy employees of the department of Gastroenterology
& Hepatology and the department of Surgery to volunteer as healthy
subjects. Subjects were included if they were male or female, between
20 and 35 years of age and when they were available on the day the
measurements took place. Exclusion criteria for healthy subjects were a
known liver disease or a systemic disease requiring medication.
2.3 | Ultrasound examination and pSWE
We sent an information letter to all eligible patients and later contacted
them by telephone to assess whether they were willing to participate
in the study. Patients were scheduled for routine ultrasound examina-
tion and pSWE at the outpatient clinic of the Gastroenterology and
Hepatology department after we received written informed consent.
We performed pSWE using the Philips Epiq7 ultrasound system
equipped with aa C5-1 broadband curved-array (Philips Healthcare
Andover, MA). Two experienced liver sonographers (P.T. and R.K., with
25 and 15 years of experience, respectively), hereinafter referred to as
observer #1 (O1) and observer #2 (O2), independently performed the
measurements in all patients according to the European Federation of
Societies for Ultrasound in Medicine and Biology (EFSUMB) guidelines
for the performance of elastography.21,22
In patients with either FNH or HCA, we measured the lesion’s size in
mm and acquired pSWE measurements from the lesion situated best in
the field of view, and preferably the largest lesion. In case there were
multiple lesions, we performed the measurements in the lesion situated
best in the field of view and preferably the largest lesion. Patients were
asked to hold their breath at the moment of the measurement. Each mea-
surement provides a quantitative value of stiffness in kilopascals (kPa). In
the analysis, we used the medians of these ten values obtained in the
lesion and of the 10 values obtained in the surrounding NLT. Additionally,
we calculated the lesion/liver stiffness-ratio (LLSR).
All healthy subjects were randomly appointed to either O1 or O2.
In each of the 10 individuals the sonographers performed two rounds
of ten measurements in the NLT at 10-min intervals.
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2.4 | Statistical analysis
We used IBM SPSS software version 21.0 (Chicago, Il) for statistical
analysis and reported continuous variables as medians and interquartile
ranges (IQR) and binary variables as frequencies (n) and percentages (%).
We used Mann-Whitney U test to assess differences for continuous var-
iables and v2 test for categorical variables. Correlation between varia-
bles was analyzed using Pearson product-moment correlation
coefficient. Performance of the ElastPQ was evaluated using receiver
operating characteristic (ROC) curves. Interpretation of the ROC curves
was based on the area under the ROC Curve (AUROC), which is a value
between 0 and 1. The accuracy of the diagnostic test was classified
using the following point system: <0.60 fail, 0.60–0.70 poor, 0.70–0.80
fair, 0.80–0.90 good and >0.90 excellent. Interobserver and intraob-
server reliabilities were assessed using two-way mixed effects consis-
tency, single measures intraclass correlation coefficient (ICC) model.
Interpretation of the ICC was based on Cohen’s kappa, also a value
between 0 and 1. Values <0.50 were classified as poor inter-rater agree-
ment, 0.50–0.75 as moderate, 0.75–0.90 as good and>0.90 as excel-
lent. A P-value of <0.05 was considered as the level of significance.
3 | RESULTS
3.1 | Patients with FNH or HCA
We found 252 patients (244 females and 8 males) with a focal liver lesion
eligible to participate in this study as they underwent both CEUS and CE-
MRI or biopsy confirming the diagnosis FNH or HCA. Thirty-three
patients were excluded because they either underwent an intervention or
because the lesion was not visible at last follow-up and 106 patients were
excluded because they were either untraceable or did not consent to par-
ticipation. One patient was deceased (unrelated to liver disease). Finally,
we scheduled pSWE for 113 patients and a total of 88 patients (23 with
HCA and 65 with FNH) were included in the study at the end (Figure 1).
Eight patients were excluded because the lesion was situated too deep for
pSWE and 17 because the lesion could not be found anymore during US
examination. O1 performed pSWE in all included patients and O2
repeated the measurements in 62 patients (13 HCA and 49 FNH).
Eighty-seven out of 88 patients included were female (Table 1). In
the FNH group, the diagnosis was confirmed by CEUS in 56 patients
FIGURE 1 Inclusion flowchart of patients with a focal liver lesion. FNH, focal nodular hyperplasia; HCA, hepatocellular adenoma; pSWE,
point shear wave elastography
TABLE 1 Baseline characteristics of patients with a focal liver
lesion
FNH (n565) HCA (n523)
Sex
Female 64 23
Male 1 0
Age (years) 41 (34–52) 43 (33–46)
Lesion diameter at diagnosis (mm) 50 (35–62) 35 (26–60)
Lesion diameter at time of study (mm) 45 (30–60) 20 (12–28)
Time since diagnosis (months) 71 (62–81) 47 (21–76)
Diagnosis CEUS
FNH 56 (86.2) 2 (8.7)
HCA 7 (10.8) 20 (87.0)
FNH or HCA 2 (3.1) 1 (4.3)
Diagnosis at CE-MRI
FNH 61 (93.8) 1 (4.3)
HCA 1 (1.5) 21 (91.3)
FNH or HCA 1 (1.5) 0
Other 0 1 (4.3)
Not performed 2 (3.1) 0
Histopathologic diagnosis
Yes 11 (16.9) 5 (21.7)
No 54 (83.1) 18 (78.3)
Values are given as n (%) or median (IQR).
CE-MRI, contrast enhanced magnetic resonance imaging; CEUS, contrast
enhanced ultrasound; FNH, focal nodular hyperplasia; HCA, hepatocellu-
lar adenoma.
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(86.2%), seven lesions were characterized as HCA and in two patients,
CEUS could not differentiate between FNH and HCA. CE-MRI con-
firmed FNH diagnosis in 61 patients (93.8%). One lesion was initially
characterized as HCA and in one patient CE-MRI could not differenti-
ate between HCA and FNH. Eleven cases of FNH (16.9%) were biopsy
proven. In the HCA group, 20 cases (87.0%) were confirmed by CEUS,
two were characterized as FNH and in one case CEUS could not differ-
entiate between FNH and HCA. CE-MRI confirmed HCA diagnosis in
21 patients (91.3%). One case was initially characterized as FNH and
another as a different benign liver tumor (angiomyolipoma). Five cases
of HCA (21.7%) were biopsy proven.
We determined the median FNH and HCA stiffness values per
observer (Table 2 and Figure 2). For both O1 and O2, the median FNH
stiffness value was significantly higher than the HCA stiffness value
(7.01 vs 4.98 kPa (P50.017) and 7.68 vs 6.00 kPa (P50.031), respec-
tively). The median NLT stiffness value for O1 was 2.41 kPa (IQR
1.13–3.45) and 3.50 kPa (2.96–4.45) for O2. For O1, the median LLSR
for FNH was 4.00 (IQR 2.05–7.00) and the median LLSR for HCA was
1.35 (IQR 0.84–2.71) (P<0.001). For O2, these values were 2.44 (IQR
1.52–4.44) for LLSR for FNH and 1.34 (IQR 0.96–1.97) for LLSR for
HCA (P50.010). No correlation between lesion size and stiffness value
was found for both FNHs and HCAs (P>0.05).
ROC analysis for lesion pSWE values showed an AUROC for dif-
ferentiating FNH from HCA of 0.67 for O1 and 0.69 for O2. Interob-
server reliability analysis showed an ICC of 0.86 for lesion stiffness
(95%CI: 0.78–0.92), 0.09 for liver stiffness (95%CI: 20.16–0.33) and
0.78 (95%CI: 0.66–0.86) for LLSR. Subgroup analysis based on lesion
longest diameter was done in 36 lesions <30 mm (median, 20 mm;
IQR, 14–25) and 52 lesions >30 mm (median. 50 mm; IQR, 40–66). It
resulted in an ICC for lesions <30 mm of 0.18 (95% CI: 0.24–0.55) and
for lesions >30 mm of 0.88 (95% CI: 0.78–0.93).
In 15 patients either the CEUS versus MRI or biopsy diagnosis did not
match, or distinction between FNH and HCA could not be made based on
that CEUS imaging modality. The stiffness values for these lesions ranged
from1.65 to 8.75 kPa for FNHs and from1.29 to 9.36 kPa forHCAs.
Fourteen HCAs were classified as inflammatory, four as steatotic
and five were unclassified. The median stiffness values for the inflam-
matory HCAs were 4.99 and 4.46 kPa for O1 and O2, respectively
(range, 1.44–10.08), 4.82 and 7.07 kPa, respectively (range, 1.29–
20.03) for the steatotic HCAs and 4.98 and 6.10 kPa, respectively
(range, 2.11–7.77 kPa) for the unclassified HCA.
TABLE 2 Stiffness values and lesion/liver stiffness ratios for focal
nodular hyperplasias and hepatocellular adenomas
Observer 1 Observer 2
Stiffness values
FNH 7.01 (4.02–13.37) 7.68 (5.37–12.99)
HCA 4.98 (2.89–7.25) 6.00 (3.83–7.07)
P-value 0.017a 0.031a
NLT 2.41 (1.13–3.45) 3.50 (2.96–4.45)
Lesion/liver stiffness ratios
FNH 4.00 (2.05–7.00) 2.44 (1.52–4.44)
HCA 1.35 (0.84–2.71) 1.34 (0.96–1.97)
P-value <0.001a 0.010a
Values are given as median (IQR). FNH, focal nodular hyperplasia; HCA,
hepatocellular adenoma; NLT, native liver tissue.
aMann-Whitney U test showed a statistically significant difference in
FNH vs HCA stiffness and lesion/liver stiffness ratios for both observers
1 and 2.
FIGURE 2 Box-and-whisker plots for lesion stiffness, native liver
tissue stiffness and lesion:liver stiffness ratio. Box: median and
IQR, whiskers: 5–95 percentiles. FNH, focal nodular hyperplasia;
HCA, hepatocellular adenoma
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3.2 | Healthy subjects
Twenty healthy subjects were included. O1 performed pSWE in the
NLT of 4 males and 6 females with a median age of 27.5 years (IQR
25.8–28.3). O2 performed pSWE in 5 males and 5 females with a
median age of 27.0 years (IQR 23.5–29.0). Intraobserver reliability anal-
ysis showed an ICC coefficient of 0.23 (95% CI: 0.13–0.73) and 0.62
(95% CI:0.02–0.89) for O1 and O2, respectively.
4 | DISCUSSION
There is a need to improve the noninvasive diagnosis of FNH and HCA in
order to avoid overtreatment of FNH and undertreatment of HCA. Due
to its benign course, FNH typically does not need treatment or follow-up.
In contrast, a proportion of HCAs do require regular surveillance or treat-
ment in the form of surgical resection because of a risk of complications.
Several preliminary studies have shown a possible benefit from pSWE in
differentiating between these two benign liver tumors. However, the
present study could not confirm the hypothesis that pSWE performed
with ElastPQ® can be used to distinguish FNH from HCA. Although
median pSWE values were significantly higher in FNHs compared to
HCAs, we were unable to determine an acceptable cutoff point for this
characterization due to the great variability in pSWE values.
These results are in disagreement with previous studies, which
suggested that pSWE was a useful supplementary method to distin-
guish FNH from HCA during conventional ultrasound. One of these
studies was by Gallotti et al.,14 who found a significant difference in
pSWE values between FNHs and HCAs. However, they did not try to
determine a cutoff point for this differentiation.
We can divide elastography methods in pSWE (as used in this
study) and multidimensional shear wave elastography. There are some
studies available evaluating the diagnostic value of multidimensional
SWE, that did determine a cutoff point for the differentiation. One of
these studies was performed by Ronot et al.,23 who found that FNH
could be differentiated from other lesions (among which HCA, heman-
giomas, focal fatty sparing, cholangiocarcinoma, and hepatocellular car-
cinoma) with an AUROC of 0.86. Another study by Brunel et al.24
focused only on the characterization of FNH and HCA and found the
highest accuracy (95%) with a cutoff stiffness value of 18.8 kPa
(AUROC 0.93). The differences between their results and ours might
be caused by the use of different software, as both these studies used
two-dimensional SWE (Aixplorer®, SuperSonic Imaging), compared
with pSWE (ElastPQ®, Philips Healthcare) in our study.
Another possible explanation for the different results may lie in dif-
ferences between cohorts. We included patients who were diagnosed
with FNH or HCA in the past, whereas the previously mentioned stud-
ies23,24 performed elastography at the moment of diagnosis. This might
explain an important difference in patients with HCA. The majority of
patients used oral contraceptives at the time of diagnosis and these
lesions often spontaneously regress after cessation of these pills.25 We
confirmed regression of HCA from 35 mm to 20 mm in a median
follow-up period of 47 months. The influence of this regression process
on the lesion stiffness remains unknown. Another remarkable
difference between the present study and the study by Brunel et al.24
is the stiffness values for the different HCA-subtypes. Brunel et al.
found higher values in inflammatory HCAs, whereas in our cohort we
found high values in both steatotic and inflammatory HCAs. We did
not perform statistical analysis on these results, as there were only four
patients in the steatotic HCA group and five in the unclassified group
and therefore statistical analysis would not be reliable.
In this study, we also checked whether pSWE could provide a con-
tributory argument in patients in whom there was a discrepancy
between CEUS and MRI or biopsy diagnosis. Unfortunately, this was
not the case, the pSWE values ranged from low to high for both lesions.
The use of pSWE for the evaluation of focal liver lesions has limita-
tions. The first limitation is that currently it cannot be used in lesions that
are situated deeper than 80 mm from the skin. In this study, we had to
exclude eight patients because the lesion was too deep. During the exe-
cution of this study, we noticed that several factors might affect a lesion’s
stiffness value. For example, higher values may be seen in lesions with a
fibrotic membrane where the pSWE region of interest exceeds the lesion
diameter, in lesions located just underneath the liver capsule or in the
proximity of one of the ligaments and in lesions with scar tissue. Lower
values may be found in lesions with intralesional arteries or veins or
lesions located in the proximity of any liver artery or vein.
In this study, we also assessed the interobserver reliability in
patients with focal liver lesions using the ICC. We found good interob-
server reliability for lesion stiffness but a poor one for the surrounding
NLT. Subgroup analysis showed a better interobserver reliability in
lesions >30 mm compared to those <30 mm. In 2012, Gallotti et al.14
also did an interobserver evaluation while performing ARFI ultrasound
imaging in patients with focal liver lesions, including hepatocellular car-
cinomas, hemangiomas, HCAs, metastases, and FNHs). They compared
the mean values between the two operators and did not find a statisti-
cally significant difference. However, we believe that the ICC is a more
valid method to assess interobserver reliability and that it would be
wise to validate other elastography software with this method.
This study also assessed the intraobserver reliability of pSWE in
determining the stiffness of NLT in healthy subjects. Remarkably, we
found poor to moderate intraobserver reliability while other studies had
good to excellent results.26,27 This is also stated in themost recent update
of the EFSUMB guidelines on the use of elastography.28 The differences
might be explained by our small sample size of healthy subjects, but could
also indicate that the performance of pSWE in determining the stiffness
of NLT in healthy subjects is not as good as the first results showed.
This study has limitations. The first is the fact that not all lesions
were biopsied and therefore only 17% of FNHs and 22% of HCAs were
pathologically proven. Although pathological examination remains the
gold standard for diagnosis of benign liver tumors, clinical practice guide-
lines advise to rely mainly on imaging findings as CE-MRI has a high sen-
sitivity and specificity. Biopsy should only be performed in case of
diagnostic uncertainty after state-of-the-art imaging.29 Second, we had
a high rate of failed pSWE examinations (25 out of 113 patients) due to
either the depth of the lesion or because the lesion could not be found
at ultrasound examination. Thirteen HCAs could not been found, as
these lesions may regress after cessation of oral contraceptives.17 We
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must highlight that this was the reason that we purposely excluded all
female patients with HCA over 50 years of age. More remarkable was
the fact that four FNHs also could not be found at ultrasound examina-
tion, as these lesions usually do not regress over time. The last limitation
is the possible skewed distribution between males and females in this
study, as only one male was included. It is known that both types of
lesions have a female predominance, although a clear relationship with
female sex steroids has only been demonstrated for HCA. Additionally,
guidelines advise to perform a resection in all men with proven HCA as
they appear to have a higher risk of malignant transformation.29
In conclusion, this study suggests that pSWE cannot reliably differ-
entiate between FNH and HCA. Additionally, both interobserver and
intraobserver reliability for pSWE measurements of the NLT were
insufficient. Interpretation of the results gained with this method
should be done with caution.
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